https://www.ucsf.edu/news/2022/09/423661/drug-turns-cancer-gene-eat-me-flag-immune-system Skip to main content University of California San Francisco Give to UCSF Home Search Small screen search [ ] [Search] Choose what type of search to perform (*) All UCSF ( ) UCSF News Center Main navigation * About + Overview + Mission & Values + Our Impact o Achievements o Economic Impact o UCSF in the Community Give to UCSF + History + Facts & Figures o Budget o Inventions & Entrepreneurship o UCSF Fact Sheet Give to UCSF + Administration o Campus Leaders o Chancellor o Executive Vice Chancellor & Provost o Community & Government Relations o Diversity & Outreach o Finance & Administrative Services o Legal Affairs o Office of Communications o University Development & Alumni Relations Give to UCSF + Locations Give to UCSF * Patient Care + Overview + UCSF Medical Center + UCSF Benioff Children's Hospitals + UCSF Dental Center + Langley Porter Psychiatric Hospital and Clinics + Specialty Clinics + Clinical Trials Give to UCSF * Research + Overview + Partnerships + Office of Research + Innovation Ventures + Postdoctoral Scholars Give to UCSF * Education + Overview + Admissions + Schools & Programs o School of Dentistry o School of Medicine o School of Pharmacy o School of Nursing o Graduate Division o Global Health Sciences Give to UCSF + Resources for Students o Academic Calendar o Career Center o Financial Aid o General Catalog o Library o Registrar o Student Success Guide Give to UCSF Give to UCSF * News & Media + UCSF News Center + UCSF Magazine + Campus News + Media Coverage + Resources for Journalists Give to UCSF * Search Give to UCSF Main navigation - Desktop * About Close About menu. About + Overview + Mission & Values + Our Impact Our Impact o Achievements o Economic Impact o UCSF in the Community + History + Facts & Figures Facts & Figures o Budget o Inventions & Entrepreneurship o UCSF Fact Sheet + Administration Administration o Campus Leaders o Chancellor o Executive Vice Chancellor & Provost o Community & Government Relations o Diversity & Outreach o Finance & Administrative Services o Legal Affairs o Office of Communications o University Development & Alumni Relations + Locations * Patient Care Close Patient Care menu. Patient Care + Overview + UCSF Medical Center + UCSF Benioff Children's Hospitals + UCSF Dental Center + Langley Porter Psychiatric Hospital and Clinics + Specialty Clinics + Clinical Trials * Research Close Research menu. Research + Overview + Partnerships + Office of Research + Innovation Ventures + Postdoctoral Scholars * Education Close Education menu. Education + Overview + Admissions + Schools & Programs Schools & Programs o School of Dentistry o School of Medicine o School of Pharmacy o School of Nursing o Graduate Division o Global Health Sciences + Resources for Students Resources for Students o Academic Calendar o Career Center o Financial Aid o General Catalog o Library o Registrar o Student Success Guide * News & Media Close News & Media menu. News & Media + UCSF News Center + UCSF Magazine + Campus News + Media Coverage + Resources for Journalists * Open or Close Search Form search [ ] Choose what type of search to perform (*) All UCSF ( ) UCSF News Center [Search] Special Notice About COVID-19 Learn about UCSF's response to the coronavirus outbreak, important updates on campus safety precautions, and the latest policies and guidance on our COVID-19 resource website. You can also access information from the CDC. Learn more Microscopy showing a biopsy of lung tumor tissue * Research * September 13, 2022 Drug Turns Cancer Gene Into 'Eat Me' Flag for Immune System UCSF-Led Study Shows Promising Pre-Clinical Results in Killing Cancer Cells Resistant to Current KRAS-Targeted Treatments By Sarah C.P. Williams Microscopy of a lung tumor biopsy by Lin Ma * Facebook * Twitter * Reddit * Email * Print Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers have developed a drug that overcomes some of these barriers, marking cancer cells for destruction by the immune system. The new therapy, described in Cancer Cell, pulls a mutated version of the protein KRAS to the surface of cancer cells, where the drug-KRAS complex acts as an "eat me" flag. Then, an immunotherapy can coax the immune system to effectively eliminate all cells bearing this flag. UCSF chemist Kevan Shokat speaks with graduate student Megan Moore UCSF chemist Kevan Shokat speaks with graduate student Megan Moore in his lab. Photo by Noah Berger "The immune system already has the potential to recognize mutated KRAS, but it usually can't find it very well. When we put this marker on the protein, it becomes much easier for the immune system," said UCSF chemist and Howard Hughes Medical Institute Investigator Kevan Shokat, PhD, who helped lead the new work. KRAS mutations are found in about one quarter of all tumors, making them one of the most common gene mutations in cancer. Mutated KRAS is also the target of sotorasib, which the Food and Drug Administration (FDA) has given preliminary approval for use in lung cancer, and the two approaches may eventually work well in combination. "It's exciting to have a new strategy leveraging the immune system that we can combine with targeted KRAS drugs," said Charles Craik, PhD, a lead study author and professor of pharmaceutical chemistry at UCSF. "We suspect that this could lead to deeper and longer responses for cancer patients." Turning Cancer Markers Inside Out The immune system typically recognizes foreign cells because of unusual proteins that jut out of their surfaces. But when it comes to cancer cells, there are few unique proteins found on their outsides. Instead, most proteins that differentiate tumor cells from healthy cells are inside the cells, where the immune system can't detect them. For many years, KRAS - despite how common it is in cancers - was considered undruggable. The mutated version of KRAS, which drives the growth of tumor cells, operates inside cells. It often has only one small change that differentiates it from normal KRAS, and doesn't have a readily visible spot on its structure for a drug to bind. But over recent decades, Shokat carried out detailed analyses of the protein and discovered a hidden pocket in mutated KRAS that a drug could block. His work contributed to the development and approval of sotorasib. [Charles_Cr]Charles Craik, PhD Sotorasib, however, doesn't help all patients with KRAS mutations, and some of the tumors it does shrink become resistant and start growing again. Shokat, Craik and their colleagues wondered whether there was another way to target KRAS. In the new work, the team shows that when ARS1620 - a targeted KRAS drug similar to sotorasib - binds to mutated KRAS, it doesn't just block KRAS from effecting tumor growth. It also coaxes the cell to recognize the ARS1620-KRAS complex as a foreign molecule. "This mutated protein is usually flying under the radar because it's so similar to the healthy protein," says Craik. "But when you attach this drug to it, it gets spotted right away." That means the cell processes the protein and moves it to its surface, as a signal to the immune system. The KRAS that was once hidden inside is now displayed as an "eat me" flag on the outside of the tumor cells. A Promising Immunotherapy With the shift of mutated KRAS from the inside to the outside of cells, the UCSF team was next able to screen a library of billions of human antibodies to identify those that could now recognize this KRAS flag. The researchers showed with studies on both isolated protein and human cells that the most promising antibody they had identified could bind tightly to the drug ARS1620 as well as the ARS1620-KRAS complex. When you attach this drug to it, it gets spotted right away. Charles Craik, PhD Then, the group engineered an immunotherapy around that antibody, coaxing the immune system's T cells to recognize the KRAS flag and target cells for destruction. They found that the new immunotherapy could kill tumor cells that had the mutated KRAS and were treated with ARS1620, including those that had already developed resistance to ARS1620. "What we've shown here is proof of principle that a cell resistant to current drugs can be killed by our strategy," says Shokat. More work is needed in animals and humans before the treatment could be used clinically. The researchers say that the new approach could pave the way not only for combination treatments in cancers with KRAS mutations, but also other similar pairings of targeted drugs with immunotherapies. "This is a platform technology," says Craik. "We'd like to go after other targets that might also move molecules to the cell surface and make them amenable to immunotherapy." Authors: In addition to Shokat and Craik, Ziyang Zhang, Peter J. Rohweder, Chayanid Ongpipattanakul, Koli Basu, Markus F. Bohn, Eli J. Dugan, Veronica Steri and Byron Hann of UCSF were also authors on the paper. Funding: The study was supported in part by the Damon Runyon Cancer Research Foundation (DRG-2281-17), the National Institutes of Health (T32 GM 064337, P41-GM103393), the Samuel Waxman Cancer Research Foundation, The Mark Foundation for Cancer Research, the Howard Hughes Medical Institute, the Innovation Ventures Philanthropy Fund and the Marcus Program in Precision Medicine. Conflicts of interest: Craik, Shokat, Zhang and Pohweder are inventors on a provisional patent application covering this work and owned by UCSF. Shokat is also an inventor on other related patents and patent applications, and is a consultant and shareholder in the following companies: Revolution Medicines, Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Mitokinin, Nested, Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma), Nextech, Radd, Totus, Vicinitas, Turning Point, Ikena, Initial Therapeutics, Vevo and BioTheryX. Topics * Cancer * Lung Cancer * Immunology * Pharmacy and Pharmacology * Precision Medicine and Personalized Medicine Recommended Reading microscopic image of pancreatic cancer cells * Research * Aug. 31, 2022 Research Reveals Mechanisms at Work in Progression of Pancreatic Cysts to Pancreatic Cancer A pregnant woman paints a nursery * Research * Aug. 29, 2022 Pregnant Women Exposed to Cancer-Causing Chemicals in Dishware, Hair Coloring, Plastics, and Pesticides Microsopy of CAS9 and IL2RA * Research * Aug. 25, 2022 A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors Stay in touch with the latest updates. Subscribe to UCSF News Are you a member of the news media? Visit the Media Center UCSF Footer Logo Follow Us: * Facebook * Twitter * YouTube * Instagram Get Involved * Become a UCSF Advocate * Volunteer at UCSF Medical Center * Start a Fundraiser * Subscribe to UCSF News Resources * A to Z Website List * Accessibility Resources * Administrative Policies * Brand Guidelines * Campus Life Services * Campus Maps * Careers at UCSF * Chancellor * Diversity & Outreach * Emergency Management * Human Resources * Library * People Directory * Police * Shuttle Schedule * UCSF Profiles (c) 2022 The Regents of The University of California * Sitemap * Site Map * Terms of Use * Report an issue with UCSF.edu website